Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.62 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2484248 | 0.92 | PTGDR2 (0.64) | PTGDR2 | |
| SCHEMBL2483991 | 0.83 | CNR1 (0.51) | PTGDR2 | |
| SCHEMBL6127700 | 0.82 | PTGDR2 (0.61) | PTGDR2AKR1B1 | |
| SCHEMBL3954635 | 0.77 | PTGDR2 (0.39) | PTGDR2AKR1B1IDO1 | |
| SCHEMBL958668 | 0.77 | PTGDR2 (1.00) | PTGDR2AKR1B1 | |
| SCHEMBL3960401 | 0.74 | AKR1B1 (0.41) | AKR1B1CYP2C9IDO1 | |
| SCHEMBL4976847 | 0.74 | TRAP1 (0.39) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL3957230 | 0.74 | ALDH1A1 (0.39) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL5135639 | 0.73 | AKR1B1 (0.38) | PTGDR2AKR1B1 | |
| SCHEMBL4976844 | 0.72 | KMT2A (0.38) | PTGDR2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236963-B2 | Tricyclic spiro derivatives as CRTH2 modulators | MERCK SERONO SA (CH) | 2012-08-07 | — | — | US | disclosed |
| US-8236963-B2 | Tricyclic spiro derivatives as CRTH2 modulators | MERCK SERONO SA (CH) | 2012-08-07 | — | — | US | disclosed |
| US-8236963-B2 | Tricyclic spiro derivatives as CRTH2 modulators | MERCK SERONO SA (CH) | 2012-08-07 | — | — | US | disclosed |
| EP-1891075-B1 | TRICYCLIC SPIRO DERIVATIVES AS CRTH2 MODULATORS | MERCK SERONO SA (CH) | 2011-10-19 | — | — | EP | disclosed |
| US-20090318486-A1 | Tricyclic spiro derivatives as CRTH2 modulators | LABORATOIRES SERONO S.A. (CH) | 2009-12-24 | — | — | US | disclosed |
| US-20090318486-A1 | Tricyclic spiro derivatives as CRTH2 modulators | LABORATOIRES SERONO S.A. (CH) | 2009-12-24 | — | — | US | disclosed |
| US-20090318486-A1 | Tricyclic spiro derivatives as CRTH2 modulators | LABORATOIRES SERONO S.A. (CH) | 2009-12-24 | — | — | US | disclosed |
| EP-1891075-A1 | TRICYCLIC SPIRO DERIVATIVES AS CRTH2 MODULATORS | LABORATOIRES SERONO S.A. (CH) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006125784-A1 | TRICYCLIC SPIRO DERIVATIVES AS CRTH2 MODULATORS | LABORATOIRES SERONO S.A. (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318486-A1 | Tricyclic spiro derivatives as CRTH2 modulators | RORB, NR3C2, NR1H2 | PTGDR2 42/4885AKR1B1 109/4885CYP2C9 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.